No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
533 |
4. Check minimum number of eventsNone |
533 |
5. Include endpointsNone |
533 |
6. Filter based on genotype QC (FinnGen only) |
506 |
Control definitions (FinnGen only)
- Control exclude
- H7_EYEOTH
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF4
- Parent code in ICD-10
- H55-H59
- Name in latin
- Nystagmus et alii motus irregulares oculi
Similar endpoints
↥List of similar endpoints to
Nystagmus and other irregular eye movements
based on the number of shared cases.
Similar with more cases:
- Other disorders of eye and adnexa
- Diseases of the eye and adnexa
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 4714 | 2279 | 2421 |
| Only index persons | 3952 | 1959 | 1993 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.07 | 0.07 | 0.07 |
| Only index persons | 0.07 | 0.07 | 0.08 |
| Median age at first event (years) | |||
| Whole population | 25.97 | 30.97 | 21.18 |
| Only index persons | 32.97 | 36.00 | 30.00 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 506 | 308 | 198 |
| Unadjusted period prevalence (%) | 0.10 | 0.11 | 0.09 |
| Median age at first event (years) | 46.07 | 44.23 | 48.93 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 533
- Matched controls
- 5328
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
H55
ICD-10 Finland
Nystagmus and other irregular eye movements
4503599627370496.0
307.7
521
*
AA1CG
NOMESCO Finland
Extensive MRI examination of brain with high intensity magnet
6.7
71.2
135
258
R42
ICD-10 Finland
Dizziness and giddiness
5.0
67.2
205
596
G35
ICD-10 Finland
Multiple sclerosis
16.3
59.5
52
35
H53.2
ICD-10 Finland
Diplopia
11.2
56.8
63
63
AA1BG
NOMESCO Finland
Standard MRI examination of brain with high intensity magnet
5.3
51.5
123
286
109
Kela drug reimbursment
Multiple sclerosis
15.8
46.4
41
28
AA1AD
NOMESCO Finland
CT of head and brain
3.8
46.2
204
749
XCK00
NOMESCO Finland
Perimetry
6.5
42.3
75
131
303
Kela drug reimbursment
Dimethyl fumarate, interferon beta, glatiramer acetate and teriflunomid (Multiple sclerosis)
15.7
38.5
34
23
H50.0
ICD-10 Finland
Convergent concomitant strabismus
14.0
35.1
33
25
XCW99
NOMESCO Finland
Other investigative procedure of eye
4.4
33.1
95
252
H81.2
ICD-10 Finland
Vestibular neuronitis
10.6
32.1
36
36
N29
ICPC
Neurological sympt/complt other
12.1
32.1
33
29
Z01.0
ICD-10 Finland
Examination of eyes and vision
3.3
31.2
153
582
AA1CM
NOMESCO Finland
Extensive MRI examination of brain with 3 Tesla magnet
10.1
30.9
36
38
111
Kela drug reimbursment
Epilepsy and comparable convulsive disorders
5.3
29.6
64
134
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
4.5
28.8
78
197
AA1DG
NOMESCO Finland
Very extensive MRI examination of brain with high intensity magnet
7.0
28.5
45
69
XA800
NOMESCO Finland
Neuropsychological investigation
5.1
27.8
62
133
G40.9
ICD-10 Finland
Epilepsy, unspecified
6.5
27.6
47
78
N03AF02
ATC
oxcarbazepine; oral
6.2
26.8
48
84
R5110
NOMESCO Finland
Evaluation of the need for aids, the testing, fitting and choice of the aid, instruction in use and delivery of it
3.6
26.3
99
316
Z3229
NOMESCO Finland
Other healthcare associate professional
4.1
26.2
79
216
H54.2
ICD-10 Finland
Moderate visual impairment, binocular
35.0
25.9
33
10
N03AX14
ATC
levetiracetam; systemic
7.4
24.9
37
53
R29.8
ICD-10 Finland
Other and unspecified symptoms and signs involving the nervous and musculoskeletal systems
3.9
24.4
78
222
182
Kela drug reimbursment
Brivaracetam, eslikarbazepin, gabapentin, lacosamide, levetiracetam, perampanel, pregabalin, tiagabin and zonisamide
7.6
24.0
35
49
3795A
ICD-9 Finland
Other disorders of eye, Nystagmus and other irregular eye movements
+∞
22.0
21
*
H52.1
ICD-10 Finland
Myopia
5.1
21.2
47
100
SPAT1230
SPAT
Aid fitting and borrowing and monitoring of use
3.0
20.5
107
413
H47.2
ICD-10 Finland
Optic atrophy
41.8
19.7
24
6
H53.0
ICD-10 Finland
Amblyopia ex anopsia
8.4
18.9
25
31
N03AE01
ATC
clonazepam; systemic
4.3
18.5
50
125
157
Kela drug reimbursment
Dimethyl fumarate, glatiramer acetate, interferon beta and teriflunomid (Multiple sclerosis)
14.2
18.5
31
23
SPAT1229
SPAT
Assessment of need for aid
4.1
18.4
53
139
CK2S4
NOMESCO Finland
Plain photography of ocular fundus
4.1
18.4
53
139
Z2446
NOMESCO Finland
Social worker
3.3
18.2
75
251
L28
ICPC
Limited function/disability (L)
2.8
18.1
104
421
N03AX09
ATC
lamotrigine; oral
4.0
17.3
52
141
TAB00
NOMESCO Finland
Lumbar puncture
4.1
17.2
50
132
R1250
NOMESCO Finland
Evaluation of functional capability
6.9
17.2
27
41
R27.0
ICD-10 Finland
Ataxia, unspecified
32.7
17.2
22
7
Z2445
NOMESCO Finland
Psychologist
3.6
16.5
57
170
H52.2
ICD-10 Finland
Astigmatism
5.4
16.0
32
62
M03BX01
ATC
baclofen; systemic
6.3
15.3
26
43
PA7AD
NOMESCO Finland
CT angiography of head and neck vasculature
5.9
14.7
27
48
H51.8
ICD-10 Finland
Other specified disorders of binocular movement
154.0
14.5
15
*
H52.0
ICD-10 Finland
Hypermetropia
5.2
14.0
29
58
GD1QA
NOMESCO Finland
Supine thorax X-ray examination
2.6
13.8
90
386
I63.9
ICD-10 Finland
Cerebral infarction, unspecified
3.1
13.7
61
213
CK2X4
NOMESCO Finland
Optical coherence tomography (OCT) of ocular fundus
3.0
13.7
64
230
SPAT1215
SPAT
Assessment of need for medical rehabilitation
4.4
13.6
35
84
SPAT1223
SPAT
Implementation of physical therapy rehabilitation plan
2.1
13.3
157
871
GD1AA
NOMESCO Finland
Thorax X-ray examination
2.0
13.1
234
1506
H50.1
ICD-10 Finland
Divergent concomitant strabismus
17.2
13.1
20
12
H50.30
ICD-10 Finland
Intermittent esotropy
13.4
13.0
22
17
R4130
NOMESCO Finland
Speech therapy
4.8
13.0
30
66
G40.29
ICD-10 Finland
Localization-related (focal)(partial) symptomatic epilepsy and epileptic syndromes with complex partial seizures
6.2
12.7
22
37
164
Kela drug reimbursment
Fingolimod
32.9
12.6
16
5
N86
ICPC
Multiple sclerosis
20.6
12.5
18
9
G37.9
ICD-10 Finland
Demyelinating disease of central nervous system, unspecified
13.6
12.5
21
16
G40.22
ICD-10 Finland
Complex partial epileptic seizure with secondary generalization
5.8
12.5
23
41
N03AX12
ATC
[U] gabapentin; oral
2.4
12.1
98
463
A28
ICPC
Limited function/disability NOS
2.5
12.1
86
383
N17
ICPC
Vertigo/dizziness
2.6
12.0
75
314
L03AB07
ATC
interferon beta-1a; parenteral
13.8
12.0
20
15
H53.1
ICD-10 Finland
Subjective visual disturbances
3.2
12.0
50
168
TPH04
NOMESCO Finland
Cathetrisation of vein
2.2
12.0
125
658
SPAT1220
SPAT
Assessment of need for rehabilitation and/or rehabilitation plan
3.4
11.8
44
138
H57.1
ICD-10 Finland
Ocular pain
4.3
11.5
30
73
H27.0
ICD-10 Finland
Aphakia
25.6
11.2
15
6
I69.3
ICD-10 Finland
Sequelae of cerebral infarction
3.2
11.1
46
154
Z00.4
ICD-10 Finland
General psychiatric examination, not elsewhere classified
2.5
11.0
78
347
N05BA09
ATC
clobazam; oral
10.9
10.8
20
19
N28
ICPC
Limited function/disability (N)
9.9
10.8
21
22
Q12.0
ICD-10 Finland
Congenital cataract
28.7
10.8
14
5
R1220
NOMESCO Finland
Psychological examination of need and possibilities to rehabilitation
5.7
10.8
20
36
F83
ICD-10 Finland
Mixed specific developmental disorders
5.7
10.8
20
36
N03AG01
ATC
valproic acid; systemic, rectal
3.0
10.6
48
169
R13
ICD-10 Finland
Dysphagia
3.0
10.6
47
164
L03AX13
ATC
glatiramer acetate; parenteral
14.6
10.5
17
12
Z03.3
ICD-10 Finland
Observation for suspected nervous system disorder
3.1
10.5
44
148
E70.3
ICD-10 Finland
Albinism
+∞
10.4
10
*
4AA23, ,
NOMESCO Finland
+∞
10.4
10
*
I63.3
ICD-10 Finland
Cerebral infarction due to thrombosis of cerebral arteries
4.6
10.4
25
57
N99
ICPC
Neurological disease other
10.9
10.3
19
18
XF400
NOMESCO Finland
ECG with 12 standard connections
2.2
10.3
96
480
L04AA27
ATC
[U] fingolimod
40.9
10.0
12
*
R4120
NOMESCO Finland
Occupational therapy
2.8
9.9
51
193
353
Kela drug reimbursment
Cladribine and fingolimod
26.6
9.8
13
5
XCD10
NOMESCO Finland
Electrophysiological examination of eye
4.8
9.8
22
47
N06CA01
ATC
amitriptyline and psycholeptics; systemic
2.6
9.7
59
243
N03AX18
ATC
lacosamide; systemic
13.7
9.7
16
12
G40.20
ICD-10 Finland
Complex partial seizures with only alteration of consciousness
11.7
9.6
17
15
SPAT1222
SPAT
Counselling/guidance promoting independent living
2.3
9.6
75
348
GD1UA
NOMESCO Finland
Thorax X-ray examination outside radiological department
2.2
9.5
89
445
R2130
NOMESCO Finland
Counselling and guidance which enhance independent living
2.5
9.4
60
253
DFF59
NOMESCO Finland
Other assessment of balance
12.6
9.4
16
13
78112
ICD-8 Finland
Other symptoms referable to nervous system and special senses, Nystagmus
+∞
9.4
9
*
N18
ICPC
Paralysis/weakness
7.5
9.3
21
29
Z01.8
ICD-10 Finland
Other specified special examinations
2.0
9.3
126
725
H54.7
ICD-10 Finland
Unspecified visual loss
14.0
9.2
15
11
F79.0
ICD-10 Finland
Unspecified mental retardation, with the statement of no, or minimal, impairment of behaviour
14.0
9.2
15
11
NA1BG
NOMESCO Finland
Cervical spine MRI examination with high intensity magnet
3.1
9.2
38
127
L04AA31
ATC
[U] teriflunomide
37.4
9.0
11
*
SPAT1216
SPAT
Assessment of functional ability
2.3
9.0
75
357
N03AX11
ATC
topiramate; oral
4.0
9.0
25
64
CS444
NOMESCO Finland
Visual field testing with Octopus automated perimetry
4.0
8.8
25
65
A06AD11
ATC
lactulose; oral
2.3
8.7
67
308
N04BB01
ATC
amantadine; oral
9.2
8.6
17
19
H50.8
ICD-10 Finland
Other specified strabismus
28.0
8.5
11
*
R51.80
ICD-10 Finland
Headache
2.0
8.4
101
554
R1260
NOMESCO Finland
Evaluation of communicative skills
5.0
8.4
18
37
H40.5
ICD-10 Finland
Glaucoma secondary to other eye disorders
13.0
8.4
14
11
G91.1
ICD-10 Finland
Obstructive hydrocephalus
13.0
8.4
14
11
RS221, ,
NOMESCO Finland
4.8
8.4
19
41
F02.89*G35
ICD-10 Finland
Dementia in multiple sclerosis
+∞
8.4
8
*
CE2W4
NOMESCO Finland
Eye movement mapping
+∞
8.4
8
*
ZXE11
NOMESCO Finland
Procedure duration 60 to 89 minutes
2.5
8.3
53
224
R4110
NOMESCO Finland
Physiotherapy
1.8
8.2
153
969
DFF00
NOMESCO Finland
Pure tone audiometry
2.5
8.2
55
238
Z3226
NOMESCO Finland
Physiotherapist
1.9
8.2
111
636
AA1BD
NOMESCO Finland
Extensive CT of head and brain
4.7
8.2
19
42
Z31.5
ICD-10 Finland
Genetic counselling
2.6
8.1
48
196
JN3AE
NOMESCO Finland
Abdominal ultrasound examination
2.1
8.1
80
409
WX408
NOMESCO Finland
General anesthesy, balanced
1.8
8.0
145
911
S01XA20
ATC
artificial tears and other indifferent preparations; ophthalmic
1.7
7.9
196
1346
W01
ICD-10 Finland
Fall on same level from slipping, tripping and stumbling
1.8
7.9
152
971
N05CD08
ATC
midazolam; nasal, systemic
4.2
7.9
21
52
AAB00
NOMESCO Finland
Extirpation of intracranial lesion
8.6
7.9
16
19
CEC10
NOMESCO Finland
Recession and resection of extraocular muscle
11.0
7.8
14
13
AAF20
NOMESCO Finland
Revision of shunt of ventricle of brain
15.3
7.7
12
8
G97.0
ICD-10 Finland
Cerebrospinal fluid leak from spinal puncture
7.6
7.7
17
23
Z46.8
ICD-10 Finland
Fitting and adjustment of other specified devices
4.6
7.7
18
40
Z01.1
ICD-10 Finland
Examination of ears and hearing
2.1
7.7
82
431
183
Kela drug reimbursment
Lamotrigin and topiramate
6.9
7.6
18
27
ZXA10
NOMESCO Finland
Bilateral
1.9
7.6
99
558
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.3
7.6
60
279
R56.8
ICD-10 Finland
Other and unspecified convulsions
2.7
7.5
39
149
N07CA01
ATC
betahistine; oral
2.7
7.5
40
155
G11.9
ICD-10 Finland
Hereditary ataxia, unspecified
81.2
7.4
8
*
P85
ICPC
Mental retardation
13.6
7.4
12
9
UKC02
NOMESCO Finland
Cystoscopy
2.2
7.3
68
338
Z3231
NOMESCO Finland
Registered nurse
1.7
7.3
155
1015
WX700
NOMESCO Finland
Respiratory and circulatory monitoring
2.0
7.3
85
460
37300
ICD-8 Finland
Strabismus, Concomitans convergens
11.1
7.3
13
12
G11.2
ICD-10 Finland
Late-onset cerebellar ataxia
+∞
7.3
7
*
H53.5
ICD-10 Finland
Colour vision deficiencies
+∞
7.3
7
*
NA7CG
NOMESCO Finland
Spine and spinal cord extensive MRI examination with high intensity magnet
5.9
7.3
19
33
WX002
NOMESCO Finland
Sedation and analgesia
1.9
7.2
97
554
R3120
NOMESCO Finland
Training in mobility skills
20.3
7.2
10
5
AA7AA
NOMESCO Finland
Liquor cerebri shunt X-ray examinatin without contrast
20.3
7.2
10
5
H46
ICD-10 Finland
Optic neuritis
8.1
7.1
15
19
G81.9
ICD-10 Finland
Hemiplegia, unspecified
8.9
7.1
14
16
F32.10
ICD-10 Finland
Moderate depressive episode without somatic syndrome
2.3
7.0
57
269
A49.9
ICD-10 Finland
Bacterial infection, unspecified
2.3
7.0
52
236
R47.1
ICD-10 Finland
Dysarthria and anarthria
14.0
6.9
11
8
SPAT1296
SPAT
Other function in accordance with occupational therapy nomenclature
11.1
6.8
12
11
H51.9
ICD-10 Finland
Disorder of binocular movement, unspecified
40.6
6.8
8
*
74439
ICD-8 Finland
Congenital anomalies of eye, Cataracta NUD
40.6
6.8
8
*
G40.12
ICD-10 Finland
Simple partial seizures with secondary generalization
7.3
6.7
15
21
SPAT1301
SPAT
No procedures
1.7
6.7
158
1064
H50.2
ICD-10 Finland
Vertical strabismus
8.0
6.6
14
18
S06.0
ICD-10 Finland
Concussion
2.1
6.6
67
345
JN3AA
NOMESCO Finland
Abdominal X-ray examination without contrast
3.2
6.5
26
85
G44.2
ICD-10 Finland
Tension-type headache
2.0
6.5
78
426
-45
ICPC
Observ/health educat/advice/diet
3.7
6.5
20
55
G04BD09
ATC
trospium; oral
5.4
6.5
18
34
Z50.9
ICD-10 Finland
Care involving use of rehabilitation procedure, unspecified
3.1
6.5
27
91
R5110, ,
SPAT
2.8
6.5
32
119
7433A
ICD-9 Finland
Congenital anomalies of eye, Congenital cataract and lens anomalies
70.6
6.4
7
*
CJB10
NOMESCO Finland
Laser discission of secondary cataract
2.6
6.4
36
143
NA7DG
NOMESCO Finland
Spine and spinal cord very extensive MRI examination with high intensity magnet
6.7
6.4
15
23
H53.9
ICD-10 Finland
Visual disturbance, unspecified
3.3
6.4
24
76
AA1DM
NOMESCO Finland
Very extensive MRI examination of brain with 3 Tesla magnet
11.2
6.3
11
10
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.7
6.3
133
867
S01CA01
ATC
dexamethasone and antiinfectives; ophthalmic
1.7
6.3
148
993
7423A
ICD-9 Finland
Other congenital anomalies of nervous system, Congenital hydrocephalus
+∞
6.3
6
*
NF1AE
NOMESCO Finland
Hip joint ultrasound examination
3.8
6.2
19
52
N02BF01
ATC
gabapentin; oral
2.4
6.2
43
189
205
Kela drug reimbursment
Chronic hypertension
1.8
6.2
98
588
WYA30
NOMESCO Finland
Treatment of a patient needing special arrangements
2.2
6.1
54
263
G43.0
ICD-10 Finland
Migraine without aura [common migraine]
2.4
6.1
42
184
R39.1
ICD-10 Finland
Other difficulties with micturition
3.7
6.1
19
53
J20.9
ICD-10 Finland
Acute bronchitis, unspecified
1.8
6.0
100
607
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
216
1114
2.58
23.95
2.6
2.1
206.57
261.29
u/l
0.29
205
1052
26
32
8.49
19.78
1.1
1.0
—
—
—
0
0
45
102
4.72
18.82
1.8
2.3
183.39
152.30
e6/l
0.06
33
79
45
102
4.72
18.82
1.7
2.2
16.23
6.22
e6/l
0.60
31
76
300
1963
2.21
17.65
9.5
8.3
1.22
1.22
mmol/l
0.65
258
1698
28
43
6.81
17.63
2.6
1.3
—
—
—
0
0
29
49
6.20
16.67
1.1
1.1
—
—
—
0
0
29
51
5.95
16.02
1.1
1.1
—
—
—
0
0
101
448
2.55
14.50
1.9
2.2
355.60
373.82
nmol/l
0.39
93
422
273
1812
2.04
14.44
9.2
8.1
1.22
1.22
mmol/l
0.14
249
1668
251
1655
1.98
13.14
5.6
5.3
35.93
36.24
g/l
0.36
225
1547
23
20
11.96
12.92
1.0
1.4
128.26
141.12
nmol/l
0.43
23
20
328
2388
1.97
12.65
6.5
5.7
6.43
6.57
mmol/l
0.62
305
2203
16
5
32.90
12.63
3.3
1.2
—
—
—
0
0
247
1648
1.93
12.23
14.4
10.4
1.11
1.19
inr
0.77
61
512
24
46
5.41
12.11
1.0
1.1
—
—
—
0
0
31
77
4.21
11.55
1.2
1.2
—
—
—
0
0
415
3333
2.11
11.50
3.9
3.9
14.61
14.59
pmol/l
0.05
381
3065
304
2200
1.89
11.47
8.1
6.6
28.88
29.75
%
0.67
291
2086
302
2182
1.88
11.44
8.0
6.4
56.87
55.59
%
1.04
290
2068
341
2581
1.89
10.96
10.7
9.5
4.00
4.01
e9/l
0.02
300
2237
21
23
9.45
10.59
2.3
1.3
—
—
—
0
0
286
2095
1.79
9.75
7.1
6.4
13.02
13.28
umol/l
0.06
269
1982
13
6
22.15
9.39
1.1
2.2
—
—
—
0
0
184
1200
1.81
9.15
2.9
2.5
54.33
59.32
u/l
0.58
168
1114
20
27
7.65
9.00
1.1
1.0
0.94
1.13
u/l
—
10
14
460
3970
2.16
8.68
5.1
4.6
1.85
2.17
mu/l
0.55
429
3675
209
1454
1.72
8.10
4.8
3.2
—
—
—
0
0
204
1416
1.71
7.94
3.9
3.4
28.28
30.83
u/l
0.92
193
1350
238
1724
1.69
7.89
3.2
2.5
79.23
74.91
nmol/l
1.40
222
1573
210
1472
1.70
7.87
2.3
1.9
97.13
97.01
pmol/l
0.01
129
758
138
865
1.80
7.63
1.7
1.5
20.49
21.59
nmol/l
0.35
123
739
58
266
2.32
7.60
2.2
2.9
64.32
66.74
g/l
1.26
53
248
100
576
1.91
7.20
9.5
7.7
1.10
1.13
mmol/l
0.37
92
544
104
615
1.86
6.88
2.0
1.7
964.72
1188.21
nmol/l
2.00
80
472
168
1143
1.69
6.85
4.5
3.1
0.51
0.39
e6/l
0.13
134
843
13
14
9.48
6.81
1.2
1.1
—
—
—
0
0
13
14
9.48
6.81
1.2
1.1
—
—
—
0
0
188
1321
1.65
6.76
3.7
3.2
2.36
2.36
mmol/l
0.29
163
1173
484
4356
2.20
6.68
20.9
13.9
139.50
139.63
mmol/l
0.52
472
4235
16
25
6.56
6.68
1.1
1.2
—
—
—
0
0
484
4369
2.17
6.41
21.1
14.0
3.94
3.96
mmol/l
0.90
469
4238
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
16
28
5.85
6.18
1.1
1.2
—
—
—
0
0
45
203
2.33
6.14
1.7
1.7
—
—
—
0
0
177
1255
1.61
6.00
4.5
3.2
34.16
101.30
e6/l
0.66
144
946
445
3930
1.80
5.95
4.5
4.1
5.81
5.83
mmol/l
0.07
408
3623
9
6
15.21
5.92
1.1
1.3
—
—
—
0
0
351
2920
1.59
5.91
4.0
3.2
44.47
42.66
u/l
0.16
327
2755
12
15
8.15
5.86
1.3
1.3
—
—
—
0
0
371
3130
1.61
5.86
4.3
4.0
9.45
10.74
mm/h
1.52
345
2887
108
679
1.74
5.77
4.0
2.8
1.13
0.84
e6/l
0.27
62
371
12
16
7.64
5.66
1.3
1.2
—
—
—
0
0
9
7
13.04
5.59
1.2
1.6
—
—
—
0
0
369
3132
1.58
5.46
8.8
7.0
82.11
83.44
u/l
0.18
346
2941
128
855
1.65
5.44
3.1
2.6
4.18
6.11
e6/l
0.96
117
761
16
35
4.68
5.21
1.0
3.2
30.06
26.63
umol/l
0.66
16
35
11
16
6.99
4.97
1.2
1.1
—
—
—
0
0
38
175
2.26
4.97
5.3
6.9
0.62
0.66
%
0.39
38
175
101
651
1.68
4.89
4.3
2.9
1.88
2.24
e6/l
0.27
56
345
147
1042
1.57
4.84
2.4
2.2
3.28
2.91
mg/l
0.48
128
903
479
4391
1.89
4.80
18.9
12.4
21.03
22.05
mg/l
0.27
385
3360
107
706
1.64
4.73
4.0
3.7
225.82
569.76
ng/l
0.90
83
496
57
314
1.91
4.66
6.5
5.1
96.55
73.43
ng/l
0.99
49
291
95
611
1.67
4.63
2.0
1.9
—
—
—
0
0
30
129
2.40
4.59
2.0
1.7
—
—
—
0
0
7
5
14.15
4.58
1.3
1.6
—
—
—
0
0
95
614
1.67
4.54
3.1
2.5
12.66
13.74
umol/l
0.75
88
576
76
464
1.74
4.47
6.3
8.7
104.87
104.26
mmol/l
0.58
76
464
23
88
2.69
4.45
1.3
1.3
—
—
—
0
0
23
88
2.69
4.45
1.3
1.3
—
—
—
0
0
73
444
1.75
4.35
6.6
6.3
—
—
—
0
0
7
6
11.79
4.28
1.3
1.7
—
—
—
0
0
13
29
4.57
4.27
1.1
1.1
—
—
—
0
0
27
115
2.42
4.22
2.2
2.0
177.06
321.74
ug/l
1.07
27
105
141
1018
1.52
4.20
2.7
2.3
—
—
—
0
0
11
21
5.32
4.16
1.1
1.2
—
—
—
0
0
110
753
1.58
4.16
1.7
1.6
467.40
441.62
pmol/l
0.47
93
642
161
1203
1.48
4.05
3.6
3.4
7.56
7.93
mmol/l
0.41
147
1037
493
4605
1.94
4.02
13.0
9.5
25.61
26.27
u/l
0.45
479
4451
243
1973
1.42
3.91
2.7
2.6
—
—
—
0
0
177
1356
1.46
3.90
3.5
3.2
37.76
30.79
ng/l
0.20
125
838
28
126
2.29
3.90
1.8
2.6
—
—
—
0
0
7
8
8.84
3.78
1.3
1.4
—
—
—
0
0
9
16
5.70
3.67
3.3
1.6
—
—
—
0
0
16
56
2.91
3.65
1.6
1.8
—
—
—
0
0
51
295
1.81
3.61
4.9
3.8
1.23
1.23
mmol/l
0.25
41
260
6
6
10.09
3.50
1.2
1.5
—
—
—
0
0
130
957
1.47
3.47
3.1
3.6
1247.33
1085.46
ng/l
0.22
112
799
243
2003
1.39
3.45
3.3
2.9
159.36
98.30
ug/l
0.93
228
1873
10
22
4.61
3.44
1.3
1.1
1869.70
1732.59
miu/ml
—
10
22
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
24
107
2.30
3.43
3.4
10.0
0.52
0.35
u/ml
0.60
12
55
14
47
3.03
3.43
2.2
3.1
—
—
—
0
0
12
32
3.81
3.40
2.0
2.8
47.80
40.79
%
—
5
16
23
102
2.31
3.33
4.0
3.7
28.96
35.80
umol/l
1.01
23
93
33
170
2.00
3.31
2.2
1.9
9.25
8.58
u/l
0.08
21
131
17
66
2.63
3.24
1.6
1.7
—
—
—
0
0
79
531
1.57
3.21
3.3
2.5
20.17
23.25
%
1.55
70
465
84
573
1.55
3.20
3.1
2.4
2.38
2.40
g/l
0.11
77
535
7
11
6.43
3.19
1.1
1.2
—
—
—
0
0
28
138
2.09
3.17
2.1
1.9
—
—
—
0
0
408
3703
1.43
3.08
5.5
5.0
37.95
39.04
mmol/mol
1.87
371
3464
428
3926
1.46
2.98
3.9
3.7
1.30
1.25
mmol/l
0.66
395
3651
66
433
1.60
2.98
1.8
1.8
—
—
—
0
0
442
4092
1.47
2.81
4.5
4.1
4.54
4.69
mmol/l
2.24
407
3827
9
23
3.96
2.78
1.1
1.1
—
—
—
0
0
39
227
1.77
2.75
1.5
1.4
—
—
—
0
0
91
659
1.46
2.61
2.9
2.6
2.47
2.44
mmol/l
1.14
75
576
65
439
1.55
2.60
1.9
1.9
—
—
—
0
0
5
7
7.19
2.55
1.2
1.0
—
—
—
0
0
5
7
7.19
2.55
1.2
1.0
—
—
—
0
0
5
7
7.19
2.55
1.0
1.4
1.84
1.83
umol/24h
—
5
7
419
3865
1.39
2.51
15.1
10.9
87.90
86.83
ml/min/173m2
0.40
354
3096
56
372
1.56
2.42
10.3
7.9
1.30
1.20
mmol/l
0.08
45
282
58
389
1.55
2.41
8.9
11.1
0.81
1.01
mmol/l
0.12
47
315
243
2084
1.30
2.38
5.5
3.5
0.00
0.00
estimate
0.50
52
431
25
133
1.92
2.35
1.8
1.7
—
266.67
—
0
6
145
1161
1.34
2.30
1.5
1.4
0.89
1.35
u/ml
0.73
30
287
12
47
2.59
2.28
1.3
1.1
—
—
—
0
0
241
2077
1.29
2.24
7.3
4.8
0.00
0.00
estimate
0.50
50
420
514
4971
1.94
2.19
27.8
18.2
4.51
4.54
e12/l
0.48
501
4805
120
942
1.35
2.16
2.0
2.3
1.39
1.16
mg/l
0.30
88
722
435
4067
1.38
2.16
4.5
4.0
1.42
1.47
mmol/l
1.63
402
3795
426
3972
1.36
2.13
22.0
15.1
14.73
14.50
%
0.37
415
3912
132
1056
1.33
2.10
4.2
3.9
5.88
8.93
mg/mmol
0.81
88
694
441
4138
1.38
2.09
4.8
4.4
2.68
2.80
mmol/l
1.87
405
3849
513
4967
1.86
2.04
27.9
18.2
254.80
256.82
e9/l
0.27
500
4818
513
4967
1.86
2.04
28.2
18.5
40.35
40.32
%
0.04
478
4706
242
2106
1.27
2.02
5.4
3.5
0.00
0.01
estimate
0.50
47
403
18
330
0.53
1.94
1.6
1.5
—
—
—
0
0
64
460
1.44
1.93
4.6
4.1
29.20
31.71
%
1.53
45
315
7
22
3.21
1.88
2.3
2.8
0.12
0.14
nmol/l
—
7
16
27
160
1.72
1.85
2.1
1.6
1.22
1.17
g/l
0.43
27
155
133
1088
1.30
1.79
1.7
1.7
1.37
1.39
mmol/l
0.12
119
943
40
266
1.54
1.77
1.8
1.6
—
—
—
0
0
38
254
1.53
1.65
1.9
1.6
24.50
23.49
iu/l
0.05
26
208
28
174
1.64
1.64
2.6
1.6
—
—
—
0
0
40
272
1.51
1.61
2.2
3.7
4.43
4.80
pmol/l
1.56
35
243
52
378
1.42
1.51
4.0
3.1
—
—
—
0
0
6
21
2.88
1.51
2.0
2.8
48550.00
41576.43
ug/l
—
6
21
10
45
2.24
1.47
1.2
1.6
—
—
—
0
0
7
28
2.52
1.45
1.9
3.0
—
—
—
0
0
6
22
2.75
1.43
2.8
1.8
—
—
—
0
0
14
74
1.92
1.40
2.6
2.7
16.20
16.81
%
—
7
40
9
43
2.11
1.30
1.8
2.7
106.78
106.28
mmol/l
—
9
43
6
24
2.52
1.30
1.3
1.8
1.33
8.12
u/field
—
6
17
8
34
2.37
1.29
2.5
2.3
—
—
—
0
0
15
84
1.81
1.28
3.2
3.4
5.66
4.32
e9/l
0.31
15
84
15
85
1.79
1.24
3.5
3.7
61.27
56.69
%
0.68
15
85
32
222
1.47
1.22
2.3
2.3
949.71
3160.42
u/l
—
7
89
12
64
1.89
1.18
1.2
1.1
—
—
—
0
0
8
153
0.52
1.16
1.5
1.6
—
—
—
0
0
5
114
0.43
1.13
1.4
1.6
—
—
—
0
0
130
1118
1.21
1.12
6.0
3.8
0.00
0.00
estimate
0.50
48
407
26
176
1.50
1.12
3.0
6.9
93.62
91.42
%
0.18
26
171
13
73
1.80
1.11
1.2
1.1
5.03
2.47
u/ml
—
7
32
7
31
2.27
1.10
1.0
1.4
—
—
—
0
0
13
74
1.77
1.07
1.7
1.4
—
—
—
0
0
114
973
1.22
1.06
3.5
3.0
2376.10
5356.85
umol/l
0.62
103
858
10
53
1.90
1.01
1.0
1.0
1.59
1.38
g/l
—
10
48
39
294
1.35
0.97
2.3
2.1
5.66
8.42
ug/l
0.62
34
262
63
509
1.27
0.96
4.1
3.6
6.81
7.40
umol/l
0.14
44
441
180
1615
1.17
0.96
5.9
3.5
—
—
—
0
0
11
185
0.59
0.96
1.4
1.4
—
—
—
0
0
11
185
0.59
0.96
1.4
1.4
—
—
—
0
0
11
185
0.59
0.96
1.4
1.4
—
—
—
0
0
11
185
0.59
0.96
1.4
1.4
—
—
—
0
0
7
37
1.90
0.94
2.3
1.1
—
—
—
0
0
32
427
0.73
0.93
1.7
1.8
—
—
—
0
0
10
55
1.83
0.92
1.1
1.3
0.63
0.50
nmol/l
—
10
48
6
28
2.15
0.91
1.0
2.9
14092.67
804.50
u/ml
—
6
28
86
725
1.22
0.91
1.2
1.3
11.46
31.49
iu/ml
4.43
19
230
9
155
0.57
0.89
1.3
1.6
—
—
—
0
0
8
43
1.87
0.87
1.1
1.7
—
—
—
0
0
8
43
1.87
0.87
1.1
1.7
—
—
—
0
0
8
43
1.87
0.87
1.1
1.7
—
—
—
0
0
35
455
0.75
0.86
1.5
1.6
—
—
—
0
0
21
145
1.47
0.86
1.2
1.2
—
—
—
0
0
20
137
1.48
0.85
1.7
2.4
—
—
—
0
0
15
97
1.56
0.82
1.4
1.9
—
—
—
0
0
15
97
1.56
0.82
1.4
1.9
—
—
—
0
0
42
331
1.29
0.80
2.6
2.3
11.37
12.58
nmol/l
0.41
37
305
0
25
0.00
0.79
0.0
1.2
—
—
—
0
0
8
48
1.68
0.79
1.3
1.4
—
—
—
0
0
5
96
0.52
0.78
1.0
1.1
—
—
—
0
0
5
99
0.50
0.78
2.8
3.3
4.06
11.66
umol/l
—
5
77
8
135
0.59
0.74
1.5
1.7
—
—
—
0
0
7
39
1.80
0.72
3.0
4.3
100.29
94.46
%
—
7
39
27
203
1.35
0.72
2.6
3.0
0.17
0.09
e6/l
0.26
27
196
14
93
1.52
0.70
2.1
1.4
—
—
—
0
0
15
102
1.48
0.68
4.6
2.7
—
—
—
0
0
21
153
1.39
0.68
1.5
1.4
—
—
—
0
0
7
43
1.64
0.67
2.4
3.5
2.20
2.99
nmol/l
—
7
43
49
588
0.82
0.66
3.2
2.7
0.65
0.73
ug/l
0.34
31
355
21
155
1.37
0.64
1.3
1.3
—
—
—
0
0
66
565
1.19
0.63
1.9
1.8
1.78
1.46
%
1.38
58
503
15
104
1.45
0.63
1.3
1.3
—
—
—
0
0
17
122
1.41
0.60
1.4
1.4
227.70
337.99
ug/g
—
8
65
15
105
1.44
0.60
1.6
1.8
—
—
—
0
0
26
331
0.77
0.59
1.5
1.7
—
—
—
0
0
14
195
0.71
0.57
1.6
1.5
—
—
—
0
0
6
36
1.67
0.57
1.2
1.3
—
90.00
—
0
6
15
107
1.41
0.56
1.5
1.7
—
—
—
0
0
6
37
1.63
0.55
20.8
17.2
962.50
1416.97
nmol/l
—
6
37
23
178
1.30
0.53
1.3
1.9
—
—
—
0
0
10
66
1.52
0.52
1.3
1.3
—
—
—
0
0
11
75
1.48
0.51
1.5
1.9
—
—
—
0
0
11
75
1.48
0.51
1.5
1.9
—
—
—
0
0
13
92
1.42
0.51
1.6
1.8
—
—
—
0
0
9
65
1.39
0.50
1.1
1.1
—
—
—
0
0
15
110
1.37
0.49
1.3
1.4
—
—
—
0
0
18
137
1.32
0.47
1.3
1.3
—
—
—
0
0
5
32
1.57
0.42
1.4
1.6
—
—
—
0
0
10
70
1.44
0.42
1.8
1.7
—
—
—
0
0
0
17
0.00
0.40
0.0
2.4
—
—
—
0
0
0
17
0.00
0.40
0.0
2.4
—
—
—
0
0
22
267
0.82
0.37
1.2
1.3
—
—
—
0
0
5
37
1.35
0.37
1.0
1.3
—
—
—
0
0
36
310
1.17
0.36
1.9
2.7
79.86
71.42
ml/min/173m2
0.43
14
129
16
126
1.28
0.35
1.6
1.9
—
—
—
0
0
16
127
1.27
0.33
1.0
1.2
0.39
3.40
u/ml
2.48
11
84
6
46
1.31
0.33
2.7
2.3
—
—
—
0
0
16
128
1.26
0.32
1.5
1.8
—
—
—
0
0
31
357
0.86
0.31
1.2
1.3
92.50
139.61
iu/ml
—
10
145
33
287
1.16
0.30
1.1
1.0
—
—
—
0
0
7
57
1.23
0.29
1.3
1.9
—
—
—
0
0
98
916
1.09
0.28
5.8
3.7
1.02
1.02
kg/l
0.20
16
129
11
85
1.30
0.28
1.6
4.0
25.00
26.64
mg/l
—
5
55
14
171
0.81
0.26
1.4
1.7
—
—
—
0
0
5
38
1.32
0.23
1.0
1.3
—
—
—
0
0
5
39
1.28
0.23
4.4
2.9
18.80
58.83
u/ml
—
5
39
5
39
1.28
0.23
1.8
1.8
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
—
—
0
0
0
11
0.00
0.21
0.0
2.3
—
2.72
—
0
5
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
9
111
0.81
0.20
1.9
1.7
—
99.41
—
0
21
9
111
0.81
0.20
2.2
1.3
—
—
—
0
0
43
394
1.10
0.20
2.4
2.3
29.50
31.85
u/l
0.29
34
335
6
50
1.20
0.19
1.0
1.2
—
—
—
0
0
6
50
1.20
0.19
1.5
2.7
15.41
20.44
ug/l
—
6
50
20
175
1.15
0.18
1.3
1.3
257.84
262.93
miu/ml
—
9
91
80
759
1.06
0.17
1.5
1.5
—
—
—
0
0
326
3311
0.96
0.16
3.2
3.4
—
—
—
0
0
8
71
1.13
0.16
1.3
1.8
—
—
—
0
0
6
78
0.77
0.15
1.2
1.3
2.02
3.35
ug/l
—
6
67
10
83
1.21
0.15
1.4
1.7
—
—
—
0
0
7
88
0.79
0.14
2.1
1.5
—
—
—
0
0
11
95
1.16
0.11
2.0
1.9
160.00
224.38
pmol/l
1.31
11
89
102
988
1.04
0.11
4.6
4.5
1.54
2.34
ug/l
1.46
94
889
5
45
1.11
0.10
1.0
1.0
—
—
—
0
0
15
135
1.11
0.09
2.1
1.8
50.40
35.39
nmol/l
1.22
15
128
67
695
0.96
0.09
1.3
1.3
1.37
6.84
u/ml
2.98
24
282
11
97
1.14
0.09
1.4
1.3
—
28.35
—
0
11
71
734
0.96
0.09
2.2
2.1
—
—
—
0
0
6
57
1.05
0.08
3.0
1.4
—
—
—
0
0
6
57
1.05
0.08
3.0
1.4
—
—
—
0
0
6
58
1.03
0.08
3.0
1.4
—
—
—
0
0
6
58
1.03
0.08
3.0
1.4
—
—
—
0
0
6
58
1.03
0.08
3.0
1.4
—
—
—
0
0
8
76
1.05
0.07
2.6
1.3
—
—
—
0
0
10
90
1.11
0.05
1.0
1.1
1.00
39.92
iu/ml
—
5
25
10
92
1.09
0.03
2.0
2.0
—
—
—
0
0
110
1088
1.01
0.02
1.7
1.7
—
—
—
0
0
13
137
0.95
0.01
1.2
1.2
—
—
—
0
0
66
666
0.99
0.00
2.2
1.9
—
—
—
0
0
12
120
1.00
0.00
1.4
1.7
284.20
196.85
u/ml
—
5
65
34
344
0.99
0.00
4.3
4.0
2.80
19.76
ug/l
0.76
24
282
12
124
0.97
0.00
1.4
1.6
—
—
—
0
0
14
138
1.01
0.00
1.1
1.2
—
—
—
0
0
78
785
0.99
0.00
4.1
4.1
22.64
21.56
%
0.18
26
347
5
58
0.86
0.00
3.4
1.4
—
—
—
0
0
8
82
0.97
-0.00
1.9
1.3
—
—
—
0
0
0
9
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.0
—
—
—
0
0
6
63
0.95
-0.00
2.2
1.8
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
5
52
0.96
-0.00
2.2
1.6
—
—
—
0
0
6
59
1.02
-0.00
1.7
1.6
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.6
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint H7_NYSTAGMUS and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_NYSTAGMUS | 1.772 [1.39, 2.25] | < 0.001 |
| Birth year | 0.994 [0.99, 1.0] | 0.166 |
During the follow-up period (1.1.1998 — 31.12.2019), 175 out of 1946 females with H7_NYSTAGMUS died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| H7_NYSTAGMUS | 2.021 [1.62, 2.52] | < 0.001 |
| Birth year | 0.986 [0.98, 1.0] | 0.003 |
During the follow-up period (1.1.1998 — 31.12.2019), 210 out of 2046 males with H7_NYSTAGMUS died.
Mortality risk
Mortality risk for people of age
years, who have H7_NYSTAGMUS.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.126% | 0.334% |
| 5 | 1.05% | 2.326% |
| 10 | 2.605% | 5.471% |
| 15 | 4.768% | 10.192% |
| 20 | 8.138% | 17.425% |
Relationships between endpoints
↥Index endpoint: H7_NYSTAGMUS – Nystagmus and other irregular eye movements
GWS hits: 1
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data